| Literature DB >> 35955241 |
Aleksandra Izabela Banasiak1, Adrian Racki1, Marcin Małek2, Adrian Chlanda1.
Abstract
Although there are several methods for fabricating nanofibrous scaffolds for biomedical applications, electrospinning is probably the most versatile and feasible process. Electrospinning enables the preparation of reproducible, homogeneous fibers from many types of polymers. In addition, implementation of this technique gives the possibility to fabricated polymer-based composite mats embroidered with manifold materials, such as graphene. Flake graphene and its derivatives represent an extremely promising material for imparting new, biomedically relevant properties, functions, and applications. Graphene oxide (GO) and reduced graphene oxide (rGO), among many extraordinary properties, confer antimicrobial properties of the resulting material. Moreover, graphene oxide and reduced graphene oxide promote the desired cellular response. Tissue engineering and regenerative medicine enable advanced treatments to regenerate damaged tissues and organs. This review provides a reliable summary of the recent scientific literature on the fabrication of nanofibers and their further modification with GO/rGO flakes for biomedical applications.Entities:
Keywords: antimicrobial properties; electrospun scaffold; graphene modifications; polymeric biomaterials; tissue engineering
Year: 2022 PMID: 35955241 PMCID: PMC9369702 DOI: 10.3390/ma15155306
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.748
Figure 1Schematic diagram of the electrospinning setup. Adapted from “FullTemplateName”, by BioRender.com (2022) [28].
Figure 2Chemical structure of pristine graphene (a) and its derivatives: graphene oxide GO (b) and reduced graphene oxide rGO (c).
Figure 3Publications per year on “graphene” in the field of biomaterials. Data retrieved from Web of Science.
Antimicrobial activity of non-modified graphene derivative.
| Material | Studied Organism | Results | Reference |
|---|---|---|---|
| GO |
| The loss of viability at: 69.3% after 1 h to 89.7% after 4 h [40 µg/mL]; 91.6% at 1 h [80 µg/mL] | [ |
| rGO |
| The loss of viability at: 47.4% after 1 h to 74.9% after 4 h [40 µg/mL]; 76.8% after 1 h [80 µg/mL] | [ |
| GO/rGO |
| The loss of viability at: above 98.5% after 2 h [85 µg/mL] | [ |
| GO/rGO paper |
| No cell growth on GO paper, some number of E. coli colonies on rGO paper compared to control group | [ |
| GO |
| The loss of viability is depending on the size of GO sheets; i.e., the smaller the GO sheet, the higher is the loss of viability | [ |
| GO |
| The loss of viability at: 30% after 2 h and 50% after 24 h [85 µg/mL], (mild cytotoxicity) | [ |
| rGO |
| The loss of viability at: above 75% after 2 h [85 µg/mL] (high cytotoxicity) | [ |
| GO |
| The loss of viability at: 70% after 2 h to 85% after 4 h [100 µg/mL], above 90% after 2 h [150 µg/mL] | [ |
| rGO |
| The loss of viability at: 60% after 2 h to 85% after 4 h [100 µg/mL], above 90% after 2 h [150 µg/mL] | [ |
| GO |
| The loss of viability at: 60% after 2 h [100 µg/mL], above 90% after 2 h [250 µg/mL] | [ |
| rGO |
| The loss of viability at: 5% after 2 h [100 µg/mL], above 15% after 2 h [250 µg/mL] | [ |
| GO |
| The loss of viability at: 19.4% after 1 h to 66.1% after 4 h [50 µg/mL]; 47.8% after 1 h to 88.6% after 4 h [250 µg/mL] | [ |
| rGO |
| The loss of viability at: 10.8% after 1 h to 24.8% after 4 h [50 µg/mL]; 12.9% after 1 h to 30.5% after 4 h [250 µg/mL] | [ |
| rGO | Concentrations of rGO above 250 µg/mL almost completely inhibited fungi growth | [ |
Figure 4SEM images of E. coli bacteria in (a,b) saline solution, (c,d) in GO dispersion (40 µg/mL), (e,f) in rGO dispersion (40 µg/mL) after 2 h incubation. Reprinted with permission from [75]. Copyright 2011 American Chemical Society.
Figure 5A. niger fungi growth in rGO dispersions with different concentrations (0–500 μg/mL) after 7-day incubation. Reprinted from [81] with permission from Elsevier.
Figure 6Antiviral activity of GO (6 μg/mL) on PK-15 cells (A) and Vero cells (B). (A) Cells infected with PRV of 200 or 2000 pfu. (B) Cells infected with PEDV of 200 or 2000 pfu. Clear spots represent the amount of virus. Mock-infected cells serve as a control. Reprinted with permission from [89]. Copyright 2015 American Chemical Society.
Figure 7Images of nanofibrous scaffolds with inoculated cells stained with DAPI: (a) without modification, (b) modified with GO, (c) modified with rGO. Reproduced with permission [94] © IOP Publishing.
Figure 8Confocal microscopy images (a,b) of fibrous scaffolds with ATDC5 cells after three-day culture with piezoelectric stimulation. Reprinted from [98] with permission from Elsevier.
Figure 9Confocal microscopy images of fibrous scaffolds with ENCP cells after cell culture: (a,b) fabricated from polycaprolactone-gelatin, then placed in rGO solution, (c,d) in which rGO was also already added to the polymer PG matrix, (e) chart of the area covered by live and dead ENCP cells on the fibrous materials. Reprinted with permission from [99]. Copyright 2022 American Chemical Society.
Figure 10Images of mMSC and PC12-L cell proliferation on PCL scaffolds modified by GO, after 3 days of cell culture with different concentrations of GO (wt%). Reprinted from [100] with permission from Elsevier.
Figure 11Images of immunofluorescence staining of S-100 and NF-200 in the regenerated nerve tissues (autograft, unmodified scaffold, scaffold modified by rGO). Scale bar equals 50 μm. Reprinted from [101] with permission from Elsevier.
Figure 12Microscopic images of fibroblasts on fibrous materials, reprinted from [104].
GO and rGO functionality related with the regeneration of different tissues.
| Field of Regenerative Medicine | Polymer | Cell Type | Modifier Substance | Results | Reference |
|---|---|---|---|---|---|
| myocardial regeneration | polyurethane | stem cells | rGO | increased adhesion to substrate, improved proliferation; differentiation of cells into myocardial cells | [ |
| skeletal muscle regeneration | polyaniline, polyacrylonitrile | stem cells | GO/rGO | increased adhesion to the substrate, improved cell proliferation, differentiation | [ |
| regeneration of the nervous system | polyhydroxyalkanolane (PHA) | Schwann cells | rGO/Au | promoting proliferation and migration | [ |
| myocardial regeneration/regeneration of the nervous system | poly(esteramid) (PEA), chitosan | stem cells | rGO | differentiation | [ |
| cartilage regeneration | poly(L-lactic acid) (PLLA) | ATDC9 cells | rGO/PDA | improved proliferation, increased cell adhesion and biocompatibility | [ |
| regeneration of the nervous system | polycaprolactone-gelatin (PG) | ENPC cells | GO/rGO | promoting proliferation, migration and differentiation | [ |
| regeneration of the nervous system/bone regeneration | polycaprolactone | mMSC cells, PC12-L cells | GO/rGO | promoted adhesion, spreading and maturation, significantly increased differentiation | [ |
| regeneration of the nervous system | antheraea pernyi silk fibroin (ApF), poly(L-lactic acid-co-caprolactone) (PLCL) | Schwann cells, PC12 cells | GO/rGO | promoted migration and proliferation of Schwann cells and growth and differentiation of PC12 cells | [ |
| regeneration of the nervous system | poly(L-lactic acid) (PLLA) | MC3T3-E1 cells | HA/GO | promoting proliferation and adhesion | [ |
| regeneration of the nervous system | silk fibroin (SF) | NG108-15 cells | GO/rGO | promote proliferation and metabolic activity | [ |
| skin regeneration | chitosan | NCTC fibroblasts | rGO/TEPA | promote cell viability and proliferation | [ |